Evaluation of Plasma Concentration of the Antiarrhythmic Agent for Treatment of Fetus Tachycardia

Research Project

Project/Area Number	23591607
Research Category	Grant-in-Aid for Scientific Research (C)
Allocation Type	Multi-year Fund
Section	一般
Research Field	Embryonic/Neonatal medicine
Research Institution	Kinki University
Principal Investigator	KOTAKE Takeshi 近畿大学, 薬学部, 教授 (40450887)
Research Collaborator	KATSURAGI Shinji IKEDA Tomoaki
Project Period (FY)	2011-04-28 – 2016-03-31
Project Status	Completed (Fiscal Year 2015)
Budget Amount *help	¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000) Fiscal Year 2015: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000) Fiscal Year 2014: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000) Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2012: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000) Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Keywords	胎児不整脈 / 抗不整脈薬 / 薬物血中濃度 / 経胎盤的胎児治療
Outline of Final Research Achievements	This study was conducted in 32 hospitalized patients (average age 31.2, average weight 59.0) to investigate pharmacokinetics and pharmacodynamic. The mean cord blood/maternal plasma concentration of DX (16 examples) and ST (7 examples) was 67.6% and 73.9%, respectively.As for the dosage, a correlation was found in both DX plasma concentrations (26 examples) (P<0.001) and ST plasma concentration (12 examples) (P=0.04). There was a correlation tendency between DX plasma concentration and serum creatinine (Scr) (P=0.06), was not a significant correlation between ST plasma concentration and Scr (P=0.18). Furthermore, maternal heart rate related to DX plasma concentration weakly (P=0.09), but did not relate to ST plasma concentration (P=0.51). Treatment of fetus tachycardia made fetal atrial heart rate decreased like log approximation. It is expected to apply for approval of health insurance treatment by analyzing more additional target cases.